Double Trouble—COVID-19 and the Widespread Use of Corticosteroids: Are We Staring at an Osteonecrosis Epidemic?

Gautam M. Shetty¹,²

Received: 23 June 2021 / Accepted: 10 October 2021 / Published online: 26 October 2021
© Indian Orthopaedics Association 2021

Abstract

Background  A combination of immune-mediated vascular damage and routine use of systemic corticosteroid (CS) therapy in COVID-19 may significantly increase the risk and burden of osteonecrosis (ON) after COVID-19. This narrative review explores the pathogenesis, risk factors, and possible preventive and early treatment measures for ON in COVID-19.

Methods  For this narrative review, an extensive literature search was performed using the PubMed, Medline, and Science Direct databases from January 2000 to August 2021 for relevant articles on etiopathogenesis, epidemiology, clinical manifestations, and treatment of severe acute respiratory syndrome coronavirus (SARS-CoV) infection and steroid-induced ON (SION).

Results  Pathogenesis of COVID-19, utility of corticosteroids in the treatment of COVID-19, pathogenesis of SION vis-a-vis SARS-CoV infection, associated risk factors, and early diagnosis and treatment of ON following CS therapy of SARS-CoV infection were discussed.

Conclusion  Preliminary data of COVID-19 and similar trends from the SARS 2003 epidemic indicate that the “angiocentric” pathogenesis of SARS-CoV-2 and treatment with high-dose CS may increase the risk of ON in COVID-19 patients. Risk stratification based on CS intake during COVID-19 treatment can help identify subjects at moderate to high-risk for ON where early preventive and follow-up plans can be initiated.

Keywords  COVID-19 · Pandemic · Osteonecrosis · Corticosteroids · Avascular necrosis

Introduction

As of 31 August 2021, there were over 216.8 million confirmed cases of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with over 4.5 million deaths globally due to the coronavirus disease 2019 (COVID-19) pandemic [1]. Currently, with subsequent waves of pandemic occurring in several countries, COVID-19 may become endemic around the globe due to virus mutation and “immune escape”, variations in immunity among populations, and uneven vaccine distribution [2].

Apart from a variety of symptoms, COVID-19 can cause musculoskeletal symptoms which include fatigue, myalgia, and arthralgia during the initial phase of the illness and myositis and rhabdomyolysis with severe illness [3, 4]. Clinical presentations of COVID-19 have been attributed to an immune-mediated vascular disease causing micro- and microvascular endothelial damage and hypercoagulability [5–8]. Systemic corticosteroid (CS) therapy is frequently administered to hospitalised patients with severe or critical COVID-19 and has been reported to improve survival and shorten the duration of hospitalisation [9–11]. Despite lack of clinical benefits and potential harmful effects when used in the early phase of COVID-19, CS therapy has also been widely used in non-critically ill patients with mild or moderate COVID-19 [12–14].

Steroid-induced osteonecrosis of the femoral head (ONFH) is responsible for up to 47.4% of all patients diagnosed with non-traumatic ONFH [15, 16]. The risk of steroid-induced ON (SION) depends on the cumulative and maximum dose and the underlying disease state [15, 17, 18], and may occur even with low doses, especially in the presence of co-morbidities such as diabetes [19, 20]. Although
the occurrence of SION following treatment of severe acute respiratory syndrome (SARS) during the SARS 2003 epidemic has been well reported [21–29], few have called for attention regarding ON following COVID-19 [30–32].

Although the prevalence of ON in COVID-19 is unknown and may take time to reveal itself, it is crucial to understand the pathogenesis and risk factors for ON as a consequence of COVID-19 and its treatment. Furthermore, there is an urgent need to identify preventive and early diagnostic and treatment measures in COVID-19 patients to avert a possible epidemic of ON which may occur in the coming years. Hence this narrative review explores the pathogenesis, risk factors, and possible prevention and early treatment of ON in COVID-19.

Literature Search

This narrative review aimed to look at current knowledge about the pathogenesis of the COVID-19, utility of corticosteroids in the treatment of COVID-19, pathogenesis of SION vis-à-vis SARS-CoV infection (COVID-19 and SARS 2003), and the associated risk factors, early diagnosis and treatment of ON following CS therapy of SARS-CoV infection. An extensive literature search was performed using the PubMed, Medline, and Science Direct databases from January 2000 to August 2021. The search terms used included “SARS” OR “COVID-19” OR “coronavirus” OR “severe acute respiratory syndrome coronavirus 2”, and “steroid” OR “corticosteroid” OR “glucocorticoid” OR “treatment”, and “necrosis of the femoral head” OR “osteonecrosis” OR “avascular necrosis” OR “steroid-induced osteonecrosis”, and “pathogenesis” OR “etiology”. The inclusion criteria were all cohort and case-control studies, case series, case reports, review articles, and letters to the editor related to etiology, epidemiology, pathogenesis, clinical manifestations, or treatment of the SARS-CoV infection and SION. The exclusion criteria were non-English language articles and articles which were not peer-reviewed. Although articles published in the past 21 years were primarily selected, commonly referenced or cited older publications, especially related to SION, were also included for this review. In addition, the reference lists of articles identified by this search strategy were also manually searched and relevant articles were used. The etiology, epidemiology, pathogenesis, clinical manifestations, and treatment were reviewed from relevant articles related to COVID-19, SARS 2003, and SION obtained from the literature search.

“Angiocentric” Pathogenesis of COVID-19

The SARS-CoV-2 can directly infect endothelial cells using the angiotensin converting enzyme 2 (ACE2) receptor causing immune-mediated endothelial damage [5–8, 33–36]. Several researchers have proposed this “angiocentric” inflammation, and the ensuing endothelial dysfunction as central to the pathogenesis of COVID-19 [5–8, 33–36]. Furthermore, SARS-CoV-2 elicits a severe immune response leading to activation of the coagulation cascade and hypercoagulability [6, 7, 33–36]. The vascular changes in COVID-19 include endothelialitis, vascular narrowing and disruption, thrombotic microangiopathy, capillary dysfunction, and poor tissue oxygenation [6, 7, 33–36]. This combination of a hyperinflammatory and hypercoagulable state leads to widespread breakdown of vascular function in COVID-19 [6, 7, 33–36]. Prolonged vascular inflammation seen in COVID-19 may lead to increased vascular stiffness, accelerated vascular ageing, and increased long-term risk of cardiovascular disease [37, 38]. Furthermore, drugs such as hydroxychloroquine, azithromycin, and lopinavir used in treatment of COVID-19, can compromise cardiac function, especially in subjects with pre-existing cardiovascular disease [39, 40]. Figure 1 outlines the pathogenesis of ON in COVID-19 through different pathways.

Although it primarily affects the lungs, extra-pulmonary manifestations are frequently seen in COVID-19 [41]. This could be due to the presence of ACE2 receptors in several extra-pulmonary tissues which may cause direct viral tissue damage, endothelial damage, and dysregulation of local immune responses [5, 41, 42]. The ACE2 receptor is locally expressed in skeletal muscles and bone marrow-derived stem/progenitor cells (BMSPCs) [43–45], and their targeting by SARS-CoV-2, may lead to sarcopenia, reduced muscle strength, altered skeletal repair, and anaphasic bone loss [43, 45–47]. The pathogenesis and progression of non-traumatic ON is multifactorial and involves a combination of various mechanisms such as hypercoagulability, suppression of angiogenesis, hyperadipogenesis, altered bone remodelling, and genetic predisposition [48–52]. Hence, the macro- and microvascular changes and tissue damage caused by SARS-CoV-2 infection may increase the risk of ON after COVID-19. Although the vascular pathogenesis of ON after COVID-19 has not been investigated, a recent study reported significant vascular alteration in lower limbs with higher arterial stiffness, impaired femoral artery function, reduced ability of smaller arterioles to dilate with limb movements, and reactive hyperemia among young adults tested positive for SARS-CoV-2
compared with healthy controls [53]. Similarly, patients with severe SARS-CoV-2 infection have been reported to have proximal lower-extremity arterial thrombosis characterized by a higher clot burden on CT angiography and a worse prognosis when compared to SARS-CoV-2 negative patients [54].

Corticosteroids in COVID-19 Treatment

Systemic CS such as dexamethasone (DX) and methylprednisolone (MPS) are frequently used in the treatment of hospitalised and critically ill COVID-19 patients to alleviate “cytokine storm” [13], and to reduce the need for mechanical ventilation, duration of hospitalisation, and mortality [9–11]. Furthermore, critically ill patients with severe COVID-19 may have an associated adrenal insufficiency which may require CS treatment [46]. Cano et al. [10] reported that CS was administered in 51.3% of ICU patients, in 35.3% of mechanically ventilated patients, and in 40% with severe COVID-19. Although the dosage and duration of systemic CS therapy in COVID-19 is still evolving, the standard practice is to administer intravenous (IV) DX 6 mg once a day for 10 days or IV MPS 0.5–2 mg/kg per day tapered over 15 days [9–11].

Despite greater risk of adverse events, delayed viral shedding, and mortality, when compared to standard doses [55–58], high doses of CS (up to 20 mg/day DX or 250–1000 mg/day MPS) as short pulse therapy or for longer duration (over 2–3 weeks) have been used in patients with severe COVID-19 pneumonia or acute respiratory distress syndrome (ARDS) [59, 60], in critically ill patients [61], and to prevent severe hypoxia in low resource settings [62]. Furthermore, CS therapy can cause significant systemic metabolic effects such as hyperglycemia, hyperlipidemia, and hypertension, reduced bone matrix formation, and increased bone resorption [63].

SION have been reported to occur with moderate doses administered over a long duration (> 20 mg/day of prednisolone) [64, 65], or with high doses (1-2gm/day) over a short duration [17, 66]. Studies have analysed the incidence of ON after CS treatment following the SARS 2003 epidemic [21]. Zhao et al. [21] in a meta-analysis of patients with SARS 2003, reported a SION prevalence of 26.6% (303/1137 patients) at a mean follow-up of 15.1 months (2.5–90 months), and that higher cumulative dose (relative risk of 1.57 per 5 g increase) and longer treatment duration (relative risk of 1.29 for each 10-day increment) increased the risk of SION. Furthermore, a peak dose of > 200 mg or a cumulative dose of > 4000 mg of MPS may increase the risk of multifocal (epiphyseal and diaphyseal) ON lesions [67].

The pathogenesis of SION is complex and multifactorial. Corticosteroids diminish local perfusion by inducing microvascular thrombosis and increasing intraosseous pressure by promoting intramedullary adipogenesis which causes arterial obstruction and venous stasis [15, 40, 68]. Corticosteroids also cause an imbalance in bone resorption and repair by decreasing osteoblast production, increasing osteocyte apoptosis, and prolonging osteoclast lifespan [15,
The presence of co-morbidities such as alcohol consumption [69], smoking [70], cardiovascular or cerebrovascular disease [71], may further accentuate the effect of CS in causing ON.

### Risk Factors for ON in COVID-19

Data are currently lacking on the relationship between cumulative CS dosage and ON after COVID-19. However, analysis of clinical studies which reported ON following CS therapy for SARS 2003 indicated an ON prevalence rate of 5–57.7% and the association of higher cumulative CS dose and longer duration of CS therapy with greater risk of ON (Table 2). A meta-analysis of patients from the SARS 2003 epidemic, reported that a higher cumulative dose (> 5000 mg MPS-equivalent dose) and longer treatment duration (> 10 days) increased the risk of SION [21].

A recent review article by Zhang et al. [30] analysed the risk of ONFH with CS treatment of COVID-19 by juxtaposing it with the experience and lessons learned from CS therapy used during the SARS 2003 epidemic. Based on data derived from the SARS 2003 epidemic, the authors suggested that a cumulative dose of < 5000 mg of MPS may be relatively safe and the risk of ON increased with increasing cumulative doses, with the highest risk when the total dose was about 10,000–15,000 mg of MPS [30]. However, a recent case series of three patients who developed ONFH after COVID-19 [32], reported a lower mean cumulative dose of 758 mg (400–1250 mg) MPS in their patients, which was less than the mean cumulative dose of around 2000 mg documented in the literature as causative for SION [64, 66], and for ONFH following the SARS 2003 disease (Table 2).

Although patients with COVID-19 who received higher cumulative dose and longer duration of CS may be at greater risk for ON, it may not be possible to know the actual dosage and duration of CS treatment in every patient. Hence patient history about clinical course of COVID-19 may provide important clues regarding higher dosage and longer duration of CS treatment and help identify “COVID-related” risk factors (Table 1). These include severe organised COVID-19 pneumonia, moderate to severe ARDS, and significantly elevated serum markers where high dose CS are frequently used [58, 59, 72]. Similarly, presence of co-morbidities may indicate pre-existing risk factors where even low dose CS may increase the risk of ON (Table 1).

A risk stratification system for SION in COVID-19 patients has been proposed by Zhang and Zhang [31] to identify patients with low-risk (not received CS); moderate-risk (received cumulative dose of < 2000 mg CS for < 1 week); and high-risk (received cumulative dose of ≥ 2000 mg CS for ≥ 1 week or IV pulse ≥ 80 mg/day for at least 3 days).

| Table 1 | Potential risk factors for osteonecrosis after COVID infection |
|---------|---------------------------------------------------------------|
| **COVID-related factors** |                                                   |
| Cumulative dose of > 5000 mg MPS or equivalent corticosteroid | |
| Treatment duration with corticosteroids > 10 days | |
| Severe COVID-19 pneumonia | |
| Moderate and severe ARDS | |
| ICU admission | |
| Mechanical ventilation support | |
| Elevated serum markers—IL-6 ≥ 40 pg/ml, Ferritin ≥ 300 ng/ml, Triglycerides ≥ 300 mg/L, D-dimer ≥ 1000 ng/ml | |
| **Pre-existing factors** | |
| Excessive alcohol consumption | |
| Smoking | |
| Cardiovascular or cerebrovascular disease | |
| Rheumatoid or autoimmune disorders being treated with steroids | |
| Blood disorders—hemoglobinopathy, sickle-cell anemia, coagulopathy, myeloproliferative diseases, leukemia | |
| Tumours treated with chemotherapy or ionizing irradiation | |
| Metabolic or endocrine disorders—hypercholesterolemia, hypertriglyceridemia, Gaucher disease, hyperparathyroidism, Cushing’s disease | |
| Chronic renal disease | |
| Pregnancy | |

*COVID-19* coronavirus disease 2019, *ARDS* acute respiratory distress syndrome, *ICU* intensive care unit, *IL* interleukin, *MPS* methylprednisolone
| Study                    | Country | Disease | N   | Study design | Patient details       | Cumulative CS dosage | CS therapy duration (days) | ON Prevalence | ON details | Initial Treatment                                                                 | Follow-up duration | Outcome at final follow-up                                                                 |
|-------------------------|---------|---------|-----|--------------|-----------------------|----------------------|--------------------------|-----------------|-----------|-----------------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------|
| Agarwala et al. 2021    | India   | COVID 2019 | 3 (5 hips) | C-S of ONFH | 0 F/3 M, mean age 37.3 years | 758 mg PS            | NR                       | 100%           | Ficat-Arlet stage II 100%, time of diagnosis 58 days after start of CS therapy | 70.7 days         | Mean Visual Analogue Score for pain reduced from 8 (6–9) to 2.7 (1–4)               |
| Zhang et al. 2020       | China   | SARS 2003 | 71  | OC           | 56 F/15 M, 81.5% < 40 years of age | 3450 mg MPS          | 33                       | 21%            | 15/71 patients; 23 hips; ARCO stage IIA 15%, IIB 45% IIC 30% III 10%            | 15 years          | Stable 69.5% (16/23 hips), Worseened 26% (6/23 hips); ARCO stage IIA 15%, IIB 45% IIC 30% III 10% |
| Wang et al. 2018        | China   | SARS 2003 | 4 (8 hips) | C-S of ONFH | 3 F/1 M, mean age 39.2 years | 3040–16,440 mg MPS    | NR                       | 100%           | ARCO stage IC 100%, 50% (2 patients) multifocal                               | 14 years          | ARCO stage IIB 100%                                                                  |
| Guo et al. 2014         | China   | SARS 2003 | 539 | R            | 410 F/129 M, mean age 33.7 years | 3540 mg CS           | 24.9                     | 24%            | NR                                   | NR               |                                                                                     |
| Zhao et al. 2013        | China   | SARS 2003 | 117 (190 hips) | OC of ONFH | 78 F/39 M, mean age 32.1 years | 4903 mg PE           | NR                       | 100%           | ARCO stage I 88.5%, II 11.5%, time of diagnosis 6.2 months after start of CS therapy | 7 years           | 50 hips (26%) collapsed with 64% hips collapsing during the first 3 years, 23 hips (60.5%) collapsed among hips with initial bone grafting; ARCO stage 0.5%, stage I 0.5%, II 68.5%, stage III 26%, Risks for collapse—large lesions, less viable lateral column |
| Study          | Country | Disease | N | Study design | Patient details | Cumulative CS dosage | CS therapy duration (days) | ON Prevalence | ON details | Initial Treatment | Follow-up duration | Outcome at final follow-up |
|---------------|---------|---------|---|--------------|-----------------|----------------------|-------------------------|----------------|------------|-------------------|-----------------|-----------------------------|
| Lv et al. 2009 | China   | SARS 2003 | 71 | OC           | 41 F/30 M, 89% < 40 years of age | 6000 mg MPS | 34 | 57.7% | 41/71 patients; 31 hip ON, 10 non-hip ON; ARCO stage I 71.5%, IIA 7%, IIB 7%, IIC 14%, time of diagnosis 3–4 months after start of MPS therapy | Physiotherapy | 3 years | 28.5% underwent THA (8/28 patients), Stable 69.5% (16/23 hips), Worsened 26% (6/23 hips); ARCO stage I 74% stage IIA 6.5%, IIB 6.5%, IIC 13% |
| Chan et al. 2006 | Hong Kong | SARS 2003 | 69 | R            | 43 F/28 M, median age 33 years | 1500 mg MPS | 17 | 10% | 7/69 patients; 31 hip ON, 10 non-hip ON | NR | > 90 days | NR |
| Griffith et al. 2005 | Hong Kong | SARS 2003 | 254 | OC           | 155 F/99 M, mean age 36 years | 4570 mg PE | NR | 5% | 12/254 patients, 33% asymptomatic (4/12 patients), stage IA 9.5%, IB 9.5%, IC 71%, | NR | 6.7 months | NR |
| Hong and Du 2004 | China   | SARS 2003 | 67 (with joint pain) | R           | 55 F/12 M, mean age 32.6 years | 4117.3 mg CS | NR | 41.7% | 28/67 patients, 51 joints/sites (hip, knee, fibula, talus), 16 days after start of CS therapy | NR | NR | NR |

n number of patients, SARS severe acute respiratory syndrome, COVID coronavirus disease, C-S case-series, OC observational cohort, R retrospective, ONFH osteonecrosis of the femoral head, ON osteonecrosis, F female, M male, CS corticosteroid, PS prednisolone, MPS methylprednisolone, PE prednisolone equivalent, NR not reported, ARCO Association Research Circulation Osseous, THA total hip arthroplasty
However, pre-existing risk factors should be factored in for risk stratification of ON in COVID-19 patients as their existence may cause SION even in lower cumulative doses of CS. Furthermore, the inherent “angiocentric” nature of the COVID-19 disease and its effect on limb vascularity [53, 54], may increase the risk of ON even in patients who did not receive CS therapy for COVID-19. As more clinical data become available in the coming years on the mid to long term effects of COVID-19, evidence will emerge if COVID-19 can increase the risk of ON even in the absence of CS therapy. Hence, this risk stratification system may need further modification and validation as more evidence emerges in the future.

Prevention, Early Diagnosis and Treatment of ON in COVID-19

As part of prevention, judicious use of CS with a clear indication during COVID-19 treatment should be followed. A cumulative MPS-equivalent dose of < 5000 mg and course duration < 10 days may lower the risk of ON [21]. This cumulative dose and duration may have to be further reduced in subjects with pre-existing risk factors for ON. However, since CS therapy may be life-saving and can potentially reduce morbidity, caution is urged on withholding, withdrawing, or using a suboptimal dose of CS therapy in critically ill patients with COVID-19 who might otherwise benefit from it. Methods to effectively prevent the development of SION or progression of early disease are unclear with most studies performed on animal models [15]. Intermittent rather than continuous CS treatment with a “steroid holiday” [73], and addition of lipid-lowering statins and anti-coagulants with or without a vasodilator [74], may help reduce the risk of ON. Despite encouraging results in animal models [74, 75], the efficacy of lipid lowering statins in preventing SION in human subjects is unclear [76]. However, anti-coagulants such as low-molecular weight heparin (LMWH) or enoxaparin may prevent onset and progression of SION [77–79]. Although anticoagulants are frequently administered in severe COVID-19 to prevent or treat thromboembolic complications [80], there may be a need to continue standard thromboprophylaxis in high-risk patients to prevent ON.

Early diagnosis and timely treatment of ON is necessary as many patients who undergo CS treatment for COVID-19 are young individuals in whom joint-salvaging treatment options for advanced disease are limited. Magnetic resonance imaging (MRI) evidence of ON can develop within 1 year after initiation of high dose CS therapy [21, 81, 82]. However, the interval between corticosteroid intake and development of symptomatic ON appears to be shorter (around 2–6 months) in patients with SARS-CoV infection (COVID-19 or SARS 2003 disease) (Table. 2), when compared to the 6–12 months reported for non-SARS-CoV SION [64–67]. Hence it is important to remain vigilant for the possibility of development of ON during the first year in high-risk patients after COVID-19 treatment. Clinical symptoms appear much later than radiological changes in ONFH, and are often misdiagnosed as originating from the lumbar spine or the knee joint [21, 82]. Hence, regular hip monitoring using MRI should be carried out in high-risk patients, at 3, 6, and 12 months after initiation of CS treatment for COVID-19 [82]. Apart from MRI, serum biomarkers such as serum apolipoprotein A-IV, human cartilage glycoprotein-39, interleukin 33, adiponectin, and antiphospholipid antibodies may be useful for early diagnosis of ON [83–85].

Early treatment of SION may help delay disease progression, reduce morbidity, and the risk for joint replacement surgery in such patients. Intervention depends on the stage of disease and includes bisphosphonates (oral alendronate 70 mg weekly along with IV zoledronic acid 5 mg annually) [32], or anticoagulants (low-molecular-weight heparin 5000LXU subcutaneously, once daily for 2 weeks every 6 months) with limited weight-bearing [78] for stage I disease, and simple core decompression for stage II disease [78]. Fu et al. [78], in a study of early diagnosis and treatment of 60 patients with ONFH reported no progression of disease in 76.3% of patients with stage I disease treated with LMWH and in 80% of patients with stage II disease treated with core decompression at the end of 24 months. Zhao et al. [23], in an analysis of 38 symptomatic ON hips without collapse diagnosed at a mean 6.2 months after start of CS therapy for SARS 2003 disease and treated with impacted bone grafting through femoral neck window, reported femoral head collapse among 60.5% of these hips at the end of 7 years (Table. 2). Wang et al. [28], in a case-series of four hips with ON following CS therapy for SARS 2003 disease and treated with a combination of IV Lipo-prostaglandin E1 10 µg Bid for 4 weeks, enoxaparin 6000 IU H QD for 12 weeks, and oral alendronate 10 mg QD for 1 year, reported slow progression of ONFH lesion from IC to IIB with no change in Harris hip score at the end of 14 years. Although literature is lacking on the results of early treatment of ON after COVID infection, a recent case series of three patients who developed ONFH after a mean 58 days post COVID-19 diagnosis, reported significant improvement in pain after bisphosphonate therapy at a mean follow-up of 70 days [32]. Traditional Chinese herbal medicines (e.g., Huo-Gu formula) given for 6 months after the diagnosis of ONFH in SARS 2003 patients have been reported to prevent femoral head collapse, delay replacement surgery, and maintain physical function in the long term [86].
Limitations

The pathophysiological mechanisms of ON in COVID-19, described in the current review, were derived from the pathogenesis of COVID-19 and SION related to SARS 2003 previously described in the literature. Hence these need to be further validated with in vitro, in vivo, and clinical studies. As data on ON following COVID-19 disease are scarce, most articles used in this narrative review regarding prevalence, risk factors, early diagnosis, and treatment of ON were based on previous studies of the SARS 2003 epidemic. Hence, the consequences of CS therapy in patients with COVID-19 disease and the effect of early diagnosis and treatment of ON in COVID-19 need confirmation by future clinical studies. Despite these limitations, this article is an early and much-needed attempt to understand the pathogenesis, risk factors, diagnosis, and treatment of ON as a consequence of COVID-19 and helps identify gaps in knowledge about this significant consequence of COVID-19.

Recommendations

Clinical data from the SARS 2003 epidemic indicate a greater propensity to develop ON in patients after SARS-CoV infection treated with CS. Hence, corticosteroids may have to be administered with caution, including minimizing dose and duration where feasible, and avoiding multiple types of CS for COVID-19 treatment. These include limiting cumulative MPS-equivalent dose to < 5000 mg and the total duration of CS therapy to < 10 days. With increasing number of studies being published on the efficacy of various treatment methods for COVID-19, alternatives to CS to alleviate hyperinflammation, and reduce morbidity and mortality, with a better safety profile and reduced risk of ON, may need to be explored.

Based on a risk-stratification system for ON in COVID-19, similar to the one recommended by Zhang and Zhang [31], moderate-risk (who received a cumulative dose of < 2000 mg CS for < 1 week) and high-risk (who received cumulative dose of ≥ 2000 mg CS for ≥ 1 week or IV pulse ≥ 80 mg/day for at least 3 days) subjects with COVID-19 disease may have to be prescribed specific preventive and follow-up plans on discharge [31]. These include pharmacological agents such as bisphosphonates, anticoagulants, and vasodilators which can be prescribed in moderate to high-risk subjects during COVID-19 treatment and continued after discharge to prevent ON. Regular follow-up with MRI imaging (e.g., at 3, 6, and 12 months after initiation of CS treatment for COVID-19) during the first 1–3 years after COVID-19 can help in early detection of ON in moderate to high-risk patients. A combination of physical therapy and pharmacotherapy (bisphosphonates, anticoagulants, and vasodilators) can be used to delay progression of early stage ON.

Conclusions

With successive “waves” of the COVID-19 pandemic, patients infected with SARS-CoV-2 who receive CS treatment will increase substantially in the coming years. Preliminary data of COVID-19 and similar trends from the SARS 2003 epidemic indicate that the “angiocentric” pathogenesis of SARS-CoV-2 and treatment with high-dose CS may increase the risk of ON in COVID-19 patients. Hence, healthcare systems around the world may face a significant increase in ON cases among the general population in the near future. Risk stratification based on CS intake during COVID-19 treatment can help identify subjects at moderate to high risk for ON where early preventive and follow-up plans can be initiated. Evidence regarding musculoskeletal manifestations and long-term consequences of COVID-19 and its treatment with CS continue to evolve. It is currently based on observational studies, consensus statements, expert opinion, studies from the SARS 2003 epidemic and high-quality evidence is lacking. Moving ahead, research needs to focus on in vivo and clinical studies to determine the risk and pathogenesis of ON after COVID-19 and the efficacy of various preventive and treatment modalities in these patients.

Funding

No benefits or funds were received in support of this study by any of the authors.

Declarations

Conflict of Interest The author declares that he has no conflict of interest.

Ethical Standard Statement This article does not contain any studies with human or animal subjects performed by the any of the authors.

Ethics and Institutional Review Board (IRB) Approval Not required.

Informed consent For this type of study, formal consent is not required.
References

1. No authors listed. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed 01 Sep 2021

2. Phillips, N. (2021). The coronavirus is here to stay—here’s what that means. Nature, 590(7846), 382–384. https://doi.org/10.1038/d41586-021-00396-2

3. Mehta, O. P., Bhandari, P., Raut, A., Kacimi, S. E. O., & Huy, N. T. (2021). Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Frontiers of Public Health. https://doi.org/10.3389/fpubh.2020.582932

4. Cipollaro, L., Giordano, L., Padulo, J., Oliva, F., & Maffulli, N. (2020). Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients. Journal of Orthopedic Surgery and Research, 15(1), 178. https://doi.org/10.1186/s13018-020-01702-w

5. Ramos-Casals, M., Brito-Zerón, P., & Mariette, X. (2021). Systemic and organ-specific immune-related manifestations of COVID-19. Nature Reviews Rheumatology, 17(6), 315–332. https://doi.org/10.1038/s41586-021-00396-2

6. Siddiqui, H. K., Libby, P., & Ridker, P. M. (2021). COVID-19—a vascular disease. Trends in Cardiovascular Medicine, 31(1), 1–5. https://doi.org/10.1016/j.tcm.2020.10.005

7. Østergaard, L. (2021). SARS CoV-2 related microvascular damage and consequences during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiological Reports. https://doi.org/10.14814/phy2.14726

8. Osuchowski, M. F., Winkler, M. S., Skirecki, T., et al. (2021). The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. The Lancet, 9(6), 622–642. https://doi.org/10.1016/S2213-2600(21)00218-6

9. van Paassen, J., Vos, J. S., Hoekstra, E. M., Neumann, K. M. L., Boot, P. C., & Arbous, S. M. (2020). Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Critical Care, 24(1), 696. https://doi.org/10.1186/s13054-020-03400-9

10. Romano, G. M., Cafiero, T., Frangiosa, A., & Robertis, E. (2021). Corticosteroids in patients with COVID-19: a brief review. Minerva Anestesiologica, https://doi.org/10.2337/da20-0482

11. Zhang, P., Li, J., Liu, H., et al. (2020). Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Research, 8, 1–8. https://doi.org/10.1038/s41413-020-0084-5

12. Ly, H., de Vlas, S. J., Liu, W., et al. (2009). Avascular necrosis after treatment of SARS: a 3-year longitudinal study. Tropical Medicin and International Health, 14(Suppl 1), 79–84. https://doi.org/10.1111/j.1365-3156.2008.01858.x

13. Griffith, J. F., Antonio, G. E., Kumta, S. M., et al. (2005). Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology, 235(1), 168–175. https://doi.org/10.1148 radiol.2351041010

14. Wang, W., Zhang, N., Guo, W., & Gao, F. (2018). Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: a two and a half to fourteen year follow-up. International Orthopaedics, 42(7), 1551–1556. https://doi.org/10.1007/s00264-018-3907-x

15. Hong, N., & Du, X. K. (2004). Avascular necrosis of bone in severe acute respiratory syndrome. Clinical Radiology, 59(7), 602–608. https://doi.org/10.1016/j.crad.2003.12.008

16. Zhang, B., & Zhang, S. (2020). Corticosteroid-induced osteonecrosis in COVID-19: a call for caution. Journal of Bone and Mineral Research, 35(9), 1828–1829. https://doi.org/10.1002/jbmr.4136
32. Agarwala, S. R., Vijayvargiya, M., & Pandey, P. (2021). Avascular necrosis as a part of “long COVID-19.” BMJ Case Reports. https://doi.org/10.1136/bcr-2021-242101

33. Ackermann, M., Mentzer, S. J., Kolb, M., & Jonigk, D. (2020). Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow. The European Respiratory Journal, 56(5), 2003147. https://doi.org/10.1183/13993003.03147-2020

34. Quinaglia, T., Shabani, M., Breder, I., Silber, H. A., Lima, J. A. C., & Sposito, A. C. (2021). Coronavirus disease-19: the multi-level, multi-faceted vasculopathy. Atherosclerosis, 322, 39–50. https://doi.org/10.1016/j.atherosclerosis.2021.02.009

35. Bernard, I., Limonta, D., Mahal, L. K., & Hobman, T. C. (2020). Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19. Viruses, 15(1), 29. https://doi.org/10.3390/v15010029

36. Barbosa, L. C., Gonçalves, T. L., de Araujo, L. P., Rosario, L. V. O., & Ferrer, V. P. (2021). Endothelial cells and SARS-CoV-2: an intimate relationship. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2021.106829

37. Zanoli, L., Briet, M., Emanpa, J. P., et al. (2020). Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. Journal of Hypertension, 38(9), 1682–1698. https://doi.org/10.1097/HHJ.0000000000002508

38. Bruno, R. M., Spronck, B., Hametner, B., et al. (2021). Covid-19 effects on ARTERial stiffness and vascular Ageing: CARTER Study rationale and protocol. Artery Research, 27(2), 59–68. https://doi.org/10.2991/artres.k.201124.001

39. Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2021). COVID-19 infection: Is ACE2 a potential influence factor? Angiomed, 13(4), 237–244. https://doi.org/10.1080/1062332060094211

40. Pellicori, P., Doolub, G., Wong, C. M., et al. (2021). COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Artery Research, 19: everything in and out of flow. The European Respiratory Journal, 56(5), 2003147. https://doi.org/10.1183/13993003.03147-2020

41. Gupta, A., Madhavan, M. V., Sehgal, K., et al. (2020). Extrapolmonary manifestations of COVID-19. Nature Medicine, 26(7), 1017–1032. https://doi.org/10.1038/s41591-020-0968-3

42. Fahmy, O. H., Daas, F. M., Salunkhe, V., et al. (2021). Extrapulmonary features of post-COVID-19 patients: muscle function, physical activity, mood, and sleep quality. Irish Journal of Medical Science, 6, 1–7. https://doi.org/10.1007/s11845-021-10000-6

43. Joshi, S., Balasubramanian, N., Vasam, G., & Jarajapu, Y. P. (2016). Angiotensin converting enzyme vs angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. European Journal of Pharmacology, 774, 25–33. https://doi.org/10.1016/j.ejphar.2016.01.007

44. Tuzun, S., Keles, A., Okutan, D., Yildiran, T., & Palamar, D. (2021). Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. European Journal of Physical Rehabilitation Medicine. https://doi.org/10.2373/ S1973-9087.20.06563-6

45. Mont, M. A., Salem, H. S., Pizzu, N. S., Goodman, S. B., & Jones, L. C. (2020). Nontraumatic osteonecrosis of the femoral head: where do we stand today? a 5-year update. Journal of Bone and Joint Surgery, American, 102(12), 1084–1099. https://doi.org/10.1016/j.jbjs.19.01271

46. Tuzun, S., Keles, A., Okutan, D., Yildiran, T., & Palamar, D. (2021). Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. European Journal of Physical Rehabilitation Medicine. https://doi.org/10.2373/ S1973-9087.20.06563-6

47. Mont, M. A., Salem, H. S., Pizzu, N. S., Goodman, S. B., & Jones, L. C. (2020). Nontraumatic osteonecrosis of the femoral head: where do we stand today? a 5-year update. Journal of Bone and Joint Surgery, American, 102(12), 1084–1099. https://doi.org/10.1016/j.jbjs.19.01271

48. Pellicori, P., Doolub, G., Wong, C. M., et al. (2021). Extrapolmonary features of post-COVID-19 patients: muscle function, physical activity, mood, and sleep quality. Irish Journal of Medical Science, 6, 1–7. https://doi.org/10.1007/s11845-021-02667-3

49. Gupta, A., Madhavan, M. V., Sehgal, K., et al. (2020). Extrapolmonary manifestations of COVID-19. Nature Medicine, 26(7), 1017–1032. https://doi.org/10.1038/s41591-020-0968-3

50. Pinzón, M. A., Ortiz, S., Murray, N., et al. (2021). Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS ONE. https://doi.org/10.1371/journal.pone.0252057

51. Edara, L., Suvvari, T. K., & Kutikuppala, L. V. S. (2020). High dose steroid therapy to prevent severe hypoxia in COVID-19 patients. Critical Care Explorations. 5(5), 2003147. https://doi.org/10.1183/13993003.03147-2020
patients: a potential solution for low resource clinical setting. Cureus. https://doi.org/10.7759/cureus.12330

Alessi, J., de Oliveira, G. B., Schaan, B. D., & Telo, G. H. (2020). Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetologia & Metabolic Syndrome, 12, 80. https://doi.org/10.1186/s13098-020-00583-7

Aaron, R. K., Voisinet, A., Racine, J., Ali, Y., & Feller, E. R. (2011). Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis. Annals of the New York Academy of Sciences, 1240, 38–46. https://doi.org/10.1111/j.1749-6632.2011.06218.x

Ono, K., Tohjima, T., & Komazawa, T. (1992). Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clinical Orthopaedic and Related Research, 277(4), 89–97.

Arbab, D., & König, D. P. (2016). Atraumatic femoral head necrosis in adults. Deutsches Ärzteblatt International, 113(3), 31–38. https://doi.org/10.3238/arztebl.2016.0031

Zhang, N. F., Li, Z. R., Wei, H. Y., Liu, Z. H., & Hernigou, P. (2008). Steroid-induced osteonecrosis: the number of lesions is related to the dosage. Journal of Bone and Joint Surgery British, 90(9), 1239–1243. https://doi.org/10.1302/0301-620X.90B9.20056

Wang, A., Ren, M., & Wang, J. (2018). The pathogenesis of steroid-induced osteonecrosis of the femoral head: a systematic review of the literature. Gene, 671, 103–109. https://doi.org/10.1016/j.gene.2018.05.091

Tsai, S. W., Wu, P. K., Chen, C. F., et al. (2016). Etiologies and outcome of osteonecrosis of the femoral head: etiology and outcome study in a Taiwan population. Journal of Chinese Medical Association, 79(1), 39–45. https://doi.org/10.1016/j.jcma.2015.07.010

Wen, Z., Lin, Z., Yan, W., & Zhang, J. (2017). Influence of cigarette smoking on osteonecrosis of the femoral head (ONFH): a systematic review and meta-analysis. Hip International, 27(5), 425–435. https://doi.org/10.5301/hipint.5000516

Sung, P. H., Yang, Y. H., Chiang, H. J., et al. (2018). Cardiovascular and cerebrovascular events are associated with nontraumatic osteonecrosis of the femoral head. Clinical Orthopaedics and Related Research, 476(4), 865–874. https://doi.org/10.1007/s11999-0000000000000161

López Zúñiga, M. Á., Moreno-Moral, A., Ocaña-Granados, A., et al. (2021). High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. PLoS ONE. https://doi.org/10.1371/journal.pone.0243964

Yang, L., Boyd, K., Kaste, S. C., Kamdem Kamdem, L., Rahija, R. J., & Relling, M. V. (2009). A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. Journal of Orthopaedic Research, 27(2), 169–175. https://doi.org/10.1002/jor.20733

Kang, P., Gao, H., Pei, F., Shen, B., Yang, J., & Zhou, Z. (2010). Effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. International Journal of Experimental Pathology, 91(3), 235–243. https://doi.org/10.1111/j.1365-2613.2010.00705.x

Wang, G. J., Cui, Q., & Balian, G. (2000). The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis. Clinical Orthopaedics and Related Research, 370(1), 295–310. https://doi.org/10.1097/00003086-20000100-000030

Ajmal, M., Matas, A. J., Kuskowski, M., & Cheng, E. Y. (2009). Does statin use reduce the risk of corticosteroid-related osteonecrosis in renal transplant population? Orthopaedic Clinics of North America, 40(2), 235–239. https://doi.org/10.1016/j.ocl.2009.01.004

Glueck, C. J., Freiberg, R. A., & Wang, P. (2020). Long-term anticoagulation prevents progression of stages I and II primary osteonecrosis of the hip in patients with familial thrombophilia. Orthopedics, 43(4), e208–e214. https://doi.org/10.3928/01474440-20200404-06

Fu, W., Liu, B., Wang, B., & Zhao, D. (2019). Early diagnosis and treatment of steroid-induced osteonecrosis of the femoral head. International Orthopaedics, 43(5), 1083–1087. https://doi.org/10.1007/s00264-018-4011-y

Liu, B. Y., Yang, L., Wang, B. J., et al. (2017). Prevention for glucocorticoid-induced osteonecrosis of femoral head: a long-term clinical follow-up trial. Zhonghua Yi Xue Hui, 97(41), 3213–3218. https://doi.org/10.1055/s-0040-1721664

Patelli, R., Chiasakul, T., Bauer, E., & Zwicker, J. I. (2021). Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thrombosis and Haemostasis, 121(1), 76–85. https://doi.org/10.1555/s-0040-1721664

Sakamoto, M., Shimizu, K., Iida, S., Akita, T., Moriya, H., & Nawata, Y. (1997). Osteonecrosis of the femoral head: a prospective study with MRI. Journal of Bone and Joint Surgery British, 79(2), 213–219.

Zhao, F. C., Li, Z. R., & Guo, K. J. (2012). Clinical analysis of osteonecrosis of the femoral head induced by steroids. Orthopaedic Surgery, 4(1), 28–34. https://doi.org/10.1111/j.1753-7681.2011.00163.x

Qi, X., & Zeng, Y. (2015). Biomarkers and pharmaceutical strategies in steroid-induced osteonecrosis of the femoral head: a literature review. Journal of International Medical Research, 43(1), 3–8. https://doi.org/10.1177/0306041814554724

Chen, S., Cai, Q., Xu, Y., et al. (2021). Associations between glucocorticoids, antiphospholipid antibodies and femur head necrosis in patients with SLE: a directed acyclic graph-based multicentre study. Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/s11999.0000000000000161

Ma, J., Guo, W., Li, Z., Wang, B., Li, S., & Wang, P. (2017). Hip osteonecrosis is associated with increased plasma IL-33 level. Mediators of Inflammation. https://doi.org/10.1155/2017/1732638

Huang, Z., Fu, F., Ye, H., et al. (2020). Chinese herbal Huo-Gu formula for the treatment of steroid-associated osteonecrosis of femoral head: a 14-year follow-up of convalescent SARS patients. Journal of Orthopaedic Translation, 23, 122–131. https://doi.org/10.1016/j.jot.2020.03.014

Publisher’s Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.